CHMP backs new therapy for 1L AML, triple combos for asthma

EMA’s CHMP this month recommended four new medicines for approval, including a new front-line therapy for AML and triple combination therapies for asthma.

The agency recommended approval for Daurismo glasdegib from Pfizer Inc. (NYSE:PFE) to treat newly diagnosed de novo or secondary acute myelogenous leukemia (AML) in patients who can’t receive induction chemotherapy. The SMO inhibitor is one of eight new therapies approved for AML since 2017 (see “AML’s Growing Options”)...